Home Newsfeeds Summit Insights Group Upgrades Silicon Laboratories to Buy

Summit Insights Group Upgrades Silicon Laboratories to Buy

Summit Insights Group analyst Kinngai Chan upgrades Silicon Laboratories (NASDAQ:SLAB) from Hold to Buy.

byBenzinga Newsdesk

February 2, 2023

1 minute read

Summit Insights Group analyst Kinngai Chan upgrades Silicon Laboratories (NASDAQ:SLAB) from Hold to Buy.

Solar Energy Broke Records In 2023, Why Are Shares Tumbling?

By Neil Dennis

December 7, 12:58 PM

New generating capacity and renewable energy investment both hit record levels in 2023

ENPH

News

BigBear.ai Expands Its Relationship With AWS To Deliver AI-Driven Solutions

By Benzinga Newsdesk

December 11, 9:12 AM

BigBear.ai (NYSE:BBAI), a premier provider of artificial intelligence (AI)-enabled business intelligence solutions, today announces it is working with Amazon Web Services (AWS) Professional Services (ProServe). By

AMZN

Catalyst Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application For FIRDAPSE Expanding Patient Population To Include Pediatric Patients 6 Years Of Age And Older

By Benzinga Newsdesk

September 29, 11:20 AM

CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

CPRX

JPMorgan Analyst Turns Bullish On Chinese Tech Stocks Amid Improving Economic Signs, Sees Up To 25% Surge: ‘China Macro Stabilization’ The Key

By Benzinga Neuro

June 20, 6:08 AM

A JPMorgan Chase & Co analyst, who was previously bearish on China's tech sector, is now predicting a significant increase in stock prices.

FXI

Summit Insights Group Upgrades Silicon Laboratories to Buy

Related Posts

Solar Energy Broke Records In 2023, Why Are Shares Tumbling?

BigBear.ai Expands Its Relationship With AWS To Deliver AI-Driven Solutions

Catalyst Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application For FIRDAPSE Expanding Patient Population To Include Pediatric Patients 6 Years Of Age And Older

JPMorgan Analyst Turns Bullish On Chinese Tech Stocks Amid Improving Economic Signs, Sees Up To 25% Surge: ‘China Macro Stabilization’ The Key